Objectives In low–middle-income countries, increasing levels of HIV drug resistance
(HIVDR) on second-line protease inhibitor (PI)-based regimens are a cause for concern …

Ritonavir-boosted atazanavir is an option for second-line therapy in low-and middle-income
countries (LMICs). We analyzed publicly available HIV-1 protease sequences from …

Background Treatment-simplification strategies are important tools for patient-centred
management. We evaluated long-term outcomes from a PI monotherapy switch strategy …

Aim: Polyanionic carbosilane dendrimers have been shown to be safe and block human
immunodeficiency virus type 1 (HIV-1) infection in a multifunctional manner. The aim of this …

Protease inhibitors (PIs) are the second-and last-line therapy for the majority of HIV-infected
patients worldwide. Only around 20% of individuals who fail PI regimens develop major …

Abstract Background The ANRS12286/MOBIDIP trial showed that boosted protease inhibitor
(bPI) plus lamivudine dual therapy was superior to bPI monotherapy as maintenance …

Mathematical models have evolved to capture epidemiological and infectious disease data
and complex relationships between the disease, host, and environment. Infectious disease …

Abstract Background In sub-Saharan Africa, detecting resistance-associated mutations
(RAMs) at failure of first-line ART with two NRTIs plus an NNRTI predicts improved …

Background Protease inhibitors (PI) are especially important in salvage therapy. Previous
treatment failure with a PI containing regimen may elicit resistance mutations, reducing PI …

HIV-1 Gag contributes to susceptibility of protease inhibitors (PIs) in the absence of known
resistance mutations in the protease gene. For the majority of HIV-infected patients …